Viking Therapeutics, Inc. Announced Q1 2026 Earnings on April 29, 2026, Reporting "a net loss of $158.3 million or $1.37 per share"

For the three months ended March 31, 2026, Viking Therapeutics recorded a net loss of $158.3 million or $1.37 per share, compared to a net loss of $45.6 million or $0.41 per share in the corresponding period in 2025.

Research and development expenses were $115.2 million for the first quarter of 2026, and general and administrative expenses were $14 million.

The company ended the first quarter of 2026 with cash, cash equivalents, and short-term investments of $603 million.

Management stated they anticipate having cash into 2028 and remain funded as expected.

During the first quarter of 2026, the company completed enrollment in the Phase III VANQUISH-2 clinical trial for its lead obesity compound, VK2735, a dual agonist of the GLP-1 and GIP receptors.

Participants in both the VANQUISH-1 and VANQUISH-2 studies began transitioning from a vial and syringe to an auto-injector device.

The company also completed enrollment in a Phase I maintenance dosing study for VK2735, expanding the number of subcutaneous dosing arms in this study from 4 to 8, and expects to report the results of the subcutaneous portion in the third quarter of 2026.

Following an end of Phase II meeting with the FDA, Viking elected to advance the oral tablet formulation of VK2735 into Phase III clinical development for the treatment of obesity, which it expects to initiate in the fourth quarter of 2026. In addition, the company filed an Investigational New Drug application for its novel amylin receptor agonist, VK3019, and expects to initiate a Phase I clinical trial later in the quarter.

The company also announced the appointment of Neil Aubuchon as its first Chief Commercial Officer.